Proteomics International is rolling out a commercial roadmap for a diagnostics suite targeting kidney disease, cancer, and endometriosis [1].
This shift from laboratory research to commercialization represents a significant step in the making available of specialized diagnostic tools for these conditions. By expanding into the U.S. market, the company aims to increase the accessibility of its Promarker tests across two major healthcare systems.
According to reports, the suite includes four diagnostic tests [1]. These tests are designed to identify markers for various health conditions, and the company is currently strengthening its operational infrastructure to support this launch.
To support the commercial rollout, Proteomics International has won College of American Pathologists (CAP) accreditation [3]. This accreditation is a critical regulatory requirement for operating a high-complexity clinical laboratory in the U.S.
Additionally, the company has commissioned a mass spectrometry lab in the U.S. to facilitate the Promarker tests [3]. The integration of these facilities ensures that the company can process samples and provide results within a regulatory framework that meets international standards.
While the company is moving toward commercialization, the focus remains on the precision of these diagnostic tools. The transition from 'lab coats' to commercial launch indicates a move toward scaling the same technology that was previously used in research settings.
Proteomics International continues to be based in Australia, but its current expansion into the U.S. market is a strategic move to increase its global reach. The company's roadmap provides a clear path for the rest of the diagnostic suite's deployment across both regions.
“Proteomics International is rolling out a commercial roadmap for a diagnostics suite”
The commercialization of the Promarker suite marks a transition from research-driven development to a scalable healthcare product. By securing CAP accreditation and establishing a U.S. lab, the company is removing regulatory hurdles and establishing the same infrastructure necessary for clinical adoption in the U.S. and Australia.
